RCT Data Needed on Phosphate-Lowering Agents and NDD-CKD Outcomes
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.
Investigators found a clinically significant difference in systolic blood pressure among patients with stage 3b to 4 chronic kidney disease taking and not taking lanthanum carbonate.
Adverse events limited to softened stool, modest increase in bowel movement freqeuncy
The trial demonstrated a statistically significant difference in serum phosphorus levels for the tenapanor group over the placebo group.